A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A052101

CTO #:

104000

NCT Number:

NCT05976763

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

To compare time to first progression or death (PFS1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B). PFS1 and PFS2 will be defined as follows for patients who achieve complete remission (CR) with induction therapy and are randomized to a maintenance treatment arm: Continuous treatment Arm A: time from randomization until first progression or death from any cause (PFS1). Intermittent treatment Arm B: time from randomization until second progression or death from any cause (PFS2)

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)